These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20538705)

  • 1. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands.
    Bosca I; Villar LM; Coret F; Magraner MJ; Simó-Castelló M; Alvarez-Cermeño JC; Casanova B
    Mult Scler; 2010 Jul; 16(7):810-5. PubMed ID: 20538705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta.
    Annunziata P; Giorgio A; De Santi L; Zipoli V; Portaccio E; Amato MP; Clerici R; Scarpini E; Moscato G; Iudice A; Vacca G; Orefice G; Morra VB; Maimone D
    J Neurol Sci; 2006 May; 244(1-2):97-102. PubMed ID: 16473370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measures in the first year of therapy predict the response to interferon beta in MS.
    Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
    Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
    van der Voort LF; Gilli F; Bertolotto A; Knol DL; Uitdehaag BM; Polman CH; Killestein J
    Arch Neurol; 2010 Apr; 67(4):402-7. PubMed ID: 20142519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM.
    Sola P; Mandrioli J; Simone AM; Ferraro D; Bedin R; Annecca R; Venneri MG; Nichelli PF; Merelli E
    Mult Scler; 2011 Mar; 17(3):303-11. PubMed ID: 21078694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients.
    Casanova B; Lacruz L; Villar ML; Domínguez JA; Gadea MC; Gascón F; Mallada J; Hervás D; Simó-Castelló M; Álvarez-Cermeño JC; Calles C; Olascoaga J; Ramió-Torrentà L; Alcalá C; Cervelló A; Boscá I; Pérez-Mirallles FC; Coret F
    Neurol Sci; 2018 Aug; 39(8):1423-1430. PubMed ID: 29882169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis.
    Thangarajh M; Gomez-Rial J; Hedström AK; Hillert J; Alvarez-Cermeño JC; Masterman T; Villar LM
    Mult Scler; 2008 Nov; 14(9):1208-13. PubMed ID: 18755821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
    Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Nos C; Tintoré M; Téllez N; Galán I; Pelayo R; Comabella M; Montalban X
    Ann Neurol; 2006 Feb; 59(2):344-52. PubMed ID: 16437558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
    Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta.
    Lundkvist M; Greiner E; Hillert J; Fogdell-Hahn A
    Mult Scler; 2010 Jul; 16(7):796-800. PubMed ID: 20534645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
    Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of oligoclonal IgM specificity in multiple sclerosis disease course.
    Villar L; García-Barragán N; Espiño M; Roldán E; Sádaba M; Gómez-Rial J; González-Porqué P; Alvarez-Cermeño J
    Mult Scler; 2008 Mar; 14(2):183-7. PubMed ID: 17942517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glypican 5 is an interferon-beta response gene: a replication study.
    Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A
    Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
    Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH
    Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.